<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579965</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT04579965</nct_id>
  </id_info>
  <brief_title>Misotac vs Combined Oral Contraceptive Pill in the Treatment of Symptomatic Isthmocele</brief_title>
  <official_title>Misotac vs Combined Oral Contraceptive Pill in the Treatment of Symptomatic Isthmocele</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Isthmocele is a growing concern as a cause of abnormal uterine bleeding, especially post&#xD;
      menstrual bleeding which may be present in up to 82% of these cases (Iannone et al 2019).&#xD;
&#xD;
      our trial is a randomized clinical trial in which women will be randomly allocated to either&#xD;
      medical treatment by oral contraceptive or to medical treatment by misotac.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Isthmocele is a growing concern as a cause of abnormal uterine bleeding, especially post&#xD;
      menstrual bleeding which may be present in up to 82% of these cases There is no universal&#xD;
      standard definition of isthmocele but most of the authors agree that isthmocele as a&#xD;
      myometrial discontinuity in the myometrium of the anterior uterine wall of &gt;2mm at the site&#xD;
      of a cesarean scar in non-pregnant women.&#xD;
&#xD;
      Treatment should be offered only to the symptomatic patient. Surgery, by hysteroscopy,&#xD;
      laparoscopy, laparotomy, or vaginal routes, is the most common treatment of choice even in&#xD;
      the small defect Surgery is not without complications and many women reject it as a treatment&#xD;
      option so it is reasonable to look for medical methods of management.&#xD;
&#xD;
      The pathogenesis of AUB following the development of isthmocele remains unexplained. Oral&#xD;
      contraceptive pills might represent a valid option due to a regulatory effect on the&#xD;
      endometrium. Several authors describe the effectiveness of oral contraceptives in reducing&#xD;
      bleeding disorders correlated to isthmocele.&#xD;
&#xD;
      Another theory of AUB following the development of isthmocele is that menstrual blood can be&#xD;
      collected in the defect so that it seeps slowly over the days following menstruation. This&#xD;
      mechanism is added by impaired uterine contractility at the scar area.&#xD;
&#xD;
      Misoprostol is a synthetic analog of prostaglandin E1, which increases myometrial&#xD;
      contractions so it can be used for various other indications in obstetrics and gynecology the&#xD;
      aim is to examine two different methods of medical treatment in cases of symptomatic&#xD;
      isthmocele; first regulatory effect on the endometrium (Oral contraceptive pills) and second&#xD;
      contraction of myometrium (misotac)&#xD;
&#xD;
      Patient and methods:&#xD;
&#xD;
      Women with a previous cesarean section who presented with postmenstrual spotting, and in whom&#xD;
      sonohysterography had shown a isthmocele were eligible. A isthmocele was defined as an&#xD;
      indentation in the anterior uterine wall at the site of the caesarean scar with at least 2 mm&#xD;
      depth, measured during sonohysterography.&#xD;
&#xD;
      Postmenstrual spotting needed to be present for at least three consecutive months after the&#xD;
      last cesarean section. Postmenstrual spotting was defined as two or more days of brownish&#xD;
      discharge at the end of menstrual bleeding when the total period of menstrual bleeding&#xD;
      exceeds 7 days&#xD;
&#xD;
      Exclusion criteria included any organic condition that will be the cause of that bleeding;&#xD;
      Pregnancy, (suspected) malignancies, use of any hormonal contraceptives, fibroid, infection&#xD;
      in the genital tract, etc.&#xD;
&#xD;
      Randomization After written informed consent was given, women were randomly allocated to&#xD;
      either medical treatment by oral contraceptive or to medical treatment by misotac.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postmenstrual spotting.</measure>
    <time_frame>after one month of drug treatment</time_frame>
    <description>the effect of the drugs on the number of days with postmenstrual spotting during a menstrual cycle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life, Satisfaction assessed by the VAS</measure>
    <time_frame>after one month of drug treatment</time_frame>
    <description>the effect of the drugs on Quality of life, Satisfaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dysfunctional Uterine Bleeding</condition>
  <arm_group>
    <arm_group_label>combined contraceptive pills</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>treat patients with isthmocele with oral contraceptive pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misotac</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>treat patients with isthmocele with misotac.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medical treatment of isthmocele</intervention_name>
    <description>comparison between different drugs</description>
    <arm_group_label>Misotac</arm_group_label>
    <arm_group_label>combined contraceptive pills</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with a previous cesarean section&#xD;
&#xD;
          -  who presented with postmenstrual spotting,&#xD;
&#xD;
          -  sonohysterography had shown a isthmocele&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  (suspected) malignancies,&#xD;
&#xD;
          -  use of any hormonal contraceptives,&#xD;
&#xD;
          -  fibroid,&#xD;
&#xD;
          -  infection in the genital tract&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Iannone P, Nencini G, Bonaccorsi G, Martinello R, Pontrelli G, Scioscia M, Nappi L, Greco P, Scutiero G. Isthmocele: From Risk Factors to Management. Rev Bras Ginecol Obstet. 2019 Jan;41(1):44-52. doi: 10.1055/s-0038-1676109. Epub 2019 Jan 15. Review.</citation>
    <PMID>30646424</PMID>
  </reference>
  <reference>
    <citation>Kremer TG, Ghiorzi IB, Dibi RP. Isthmocele: an overview of diagnosis and treatment. Rev Assoc Med Bras (1992). 2019 Jun 3;65(5):714-721. doi: 10.1590/1806-9282.65.5.714. Review.</citation>
    <PMID>31166450</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Yang M, Wang Q, Chen J, Ding J, Hua K. Prospective evaluation of five methods used to treat cesarean scar defects. Int J Gynaecol Obstet. 2016 Sep;134(3):336-9. doi: 10.1016/j.ijgo.2016.04.011. Epub 2016 Jun 30.</citation>
    <PMID>27473332</PMID>
  </reference>
  <reference>
    <citation>Florio P, Gubbini G, Marra E, Dores D, Nascetti D, Bruni L, Battista R, Moncini I, Filippeschi M, Petraglia F. A retrospective case-control study comparing hysteroscopic resection versus hormonal modulation in treating menstrual disorders due to isthmocele. Gynecol Endocrinol. 2011 Jun;27(6):434-8. doi: 10.3109/09513590.2010.495431. Epub 2011 Jan 4.</citation>
    <PMID>21204608</PMID>
  </reference>
  <reference>
    <citation>Tahara M, Shimizu T, Shimoura H. Preliminary report of treatment with oral contraceptive pills for intermenstrual vaginal bleeding secondary to a cesarean section scar. Fertil Steril. 2006 Aug;86(2):477-9. Epub 2006 Jun 12.</citation>
    <PMID>16769058</PMID>
  </reference>
  <reference>
    <citation>Thurmond AS, Harvey WJ, Smith SA. Cesarean section scar as a cause of abnormal vaginal bleeding: diagnosis by sonohysterography. J Ultrasound Med. 1999 Jan;18(1):13-6; quiz 17-8.</citation>
    <PMID>9952074</PMID>
  </reference>
  <reference>
    <citation>Wu HL, Marwah S, Wang P, Wang QM, Chen XW. Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis. Sci Rep. 2017 May 10;7(1):1664. doi: 10.1038/s41598-017-01892-0.</citation>
    <PMID>28490770</PMID>
  </reference>
  <reference>
    <citation>Tower AM, Frishman GN. Cesarean scar defects: an underrecognized cause of abnormal uterine bleeding and other gynecologic complications. J Minim Invasive Gynecol. 2013 Sep-Oct;20(5):562-72. doi: 10.1016/j.jmig.2013.03.008. Epub 2013 May 14. Review.</citation>
    <PMID>23680518</PMID>
  </reference>
  <reference>
    <citation>Vervoort A, van der Voet LF, Hehenkamp W, Thurkow AL, van Kesteren P, Quartero H, Kuchenbecker W, Bongers M, Geomini P, de Vleeschouwer L, van Hooff M, van Vliet H, Veersema S, Renes WB, Oude Rengerink K, Zwolsman SE, Br√∂lmann H, Mol B, Huirne J. Hysteroscopic resection of a uterine caesarean scar defect (niche) in women with postmenstrual spotting: a randomised controlled trial. BJOG. 2018 Feb;125(3):326-334. doi: 10.1111/1471-0528.14733. Epub 2017 Jul 5.</citation>
    <PMID>28504857</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 4, 2020</last_update_submitted>
  <last_update_submitted_qc>October 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University Hospital</investigator_affiliation>
    <investigator_full_name>Alaa Wageh</investigator_full_name>
    <investigator_title>Alaa Wageh Associate Professor Obstetrics and gynecology</investigator_title>
  </responsible_party>
  <keyword>Postmenstrual bleeding</keyword>
  <keyword>Isthmocele</keyword>
  <keyword>Combined Oral Contraceptive Pill</keyword>
  <keyword>Misotac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

